达格列净改善射血分数保留心衰患者运动时的动脉与静脉顺应性:CAMEO-DAPA试验启示
本研究为CAMEO-DAPA试验的二次分析,纳入37例HFpEF患者,随机接受达格列净或安慰剂治疗24周,采用侵入性血流动力学运动试验评估血管顺应性。结果显示达格列净降低峰值运动时收缩压,改善总动脉顺应性和静脉电容,并降低估算应激血容量,提示其血管效应可能部分解释临床获益。
要点
- 达格列净降低HFpEF患者峰值运动时收缩压,估测治疗差异-18.8 mmHg。
- 达格列净改善运动时总动脉顺应性和静脉电容,降低主动脉特征阻抗。
- 血管改善与体重下降相关,血压下降与运动时肺毛细血管楔压降低相关。
核心结论
- 在HFpEF患者中,达格列净改善运动时全身动脉顺应性和静脉电容,并降低主动脉特征阻抗,提示动脉壁僵硬度降低,可能部分解释SGLT2抑制剂的临床获益。
研究设计与样本
- CAMEO-DAPA试验的二次分析,37例HFpEF患者(平均年龄68±9岁,女性65%)接受达格列净或安慰剂治疗24周,基线与治疗后行侵入性血流动力学运动试验并同步超声心动图。
主要发现
- 达格列净对静息血压无显著影响,但降低峰值运动时收缩压(ETD -18.8 mmHg,95%CI -33.9至-3.7,P=0.016)。
- 达格列净改善运动时总动脉顺应性(ETD 0.06 mL/mmHg/m2,95%CI 0.003-0.11,P=0.039)和主动脉根部特征阻抗(ETD -2.6 mmHg/mL*sec,95%CI -5.1至-0.03,P=0.048),对全身血管阻力无显著影响。
- 达格列净降低静息和峰值运动时估算应激血容量(ETD -292 mmHg,95%CI -530至-53,P=0.018),并改善静脉电容(应激血容量与总血容量比值ETD -7.3%,95%CI -13.3%至-1.3%,P=0.020)。
- 上述峰值运动效应在匹配的20W运动强度下也观察到;总动脉顺应性和估算应激血容量改善与体重下降相关,收缩压降低与运动时估算应激血容量变化相关(r=0.40,P=0.019),血压降低与运动时肺毛细血管楔压降低相关(r=0.56,P<0.001)。
临床怎么用
- 对于HFpEF患者,达格列净可能通过改善运动时动脉顺应性和静脉电容来减轻血流动力学充血,支持其临床使用。
局限性
- 本研究为二次分析,样本量较小(37例),结论需在更大规模研究中验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Systemic arterial compliance and venous capacitance are typically impaired in patients with heart failure with preserved ejection fraction (HFpEF), contributing to hemodynamic congestion with stress. Sodium-glucose cotransporter-2 inhibitors reduce hemodynamic congestion and improve clinical outcomes in patients with HFpEF, but the mechanisms remain unclear. This study tested the hypothesis that Dapagliflozin would improve systemic arterial compliance and venous capacitance during exercise in patients with HFpEF. METHODS: In this secondary analysis from the CAMEO-DAPA trial (Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction Trial), 37 patients with HFpEF (mean age 68 ± 9 years, women 65%) underwent invasive hemodynamic exercise testing with simultaneous echocardiography at baseline and following treatment for 24 weeks with Dapagliflozin or placebo. Radial artery pressure (BP) was measured continuously using a fluid-filled catheter with transformation to aortic pressure, central hemodynamics were measured using high-fidelity micromanometers, and stressed blood volume was estimated from hemodynamic indices fit to a comprehensive cardiovascular model. RESULTS: There was no statistically significant effect of Dapagliflozin on resting BP, but Dapagliflozin reduced systolic BP during peak exercise (estimated treatment difference [ETD], -18.8 mm Hg [95% CI, -33.9 to -3.7] P=0.016). Reduction in BP was related to improved exertional total arterial compliance (ETD, 0.06 mL/mm Hg/m2 [95% CI, 0.003-0.11] P=0.039) and aortic root characteristic impedance (ETD, -2.6 mm Hg/mL*sec [95% CI: -5.1 to -0.03] P=0.048), with no significant effect on systemic vascular resistance. Dapagliflozin reduced estimated stressed blood volume at rest and during peak exercise (ETD, -292 mm Hg [95% CI, -530 to -53] P=0.018), and improved venous capacitance evidenced by a decline in ratio of estimated stressed blood volume to total blood volume (ETD, -7.3% [95% CI, -13.3 to -1.3] P=0.020). Each of these effects of Dapagliflozin at peak exercise were also observed during matched 20W exercise intensity. Improvements in total arterial compliance and estimated stressed blood volume were correlated with decreases in body weight, and reduction in systolic BP with treatment was correlated with the change in estimated stressed blood volume during exercise (r=0.40, P=0.019). Decreases in BP were correlated with reduction in pulmonary capillary wedge pressure during exercise (r=0.56, P<0.001). CONCLUSIONS: In patients with HFpEF, treatment with Dapagliflozin improved systemic arterial compliance and venous capacitance during exercise, while reducing aortic characteristic impedance, suggesting a reduction in arterial wall stiffness. These vascular effects may partially explain the clinical benefits with sodium-glucose cotransporter-2 inhibitors in HFpEF. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04730947.
引用
- Tada, Burkhoff, Naser, et al. Dapagliflozin Enhances Arterial and Venous Compliance During Exercise in Heart Failure With Preserved Ejection Fraction: Insights From the CAMEO-DAPA Trial. Circulation. 2024. PMID: 39101201. doi:10.1161/CIRCULATIONAHA.124.068788
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。